Jim Hsiang, MD
Radiation Oncology · Corpus Christi, TXNPI 1164531273
Payments from drug & device makers
Across 608 payments — averaging $424.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$115K
- Astellas Pharma US Inc$97K
- Amgen$23K
- Astellas Pharma Global Development$8K
- Johnson & Johnson$5K
- Pfizer$5K
- plus $6K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 130 | $114,815 |
| Astellas Pharma US Inc | 134 | $96,605 |
| Amgen | 49 | $22,857 |
| Astellas Pharma Global Development | 6 | $7,810 |
| Johnson & Johnson(2 entities) | 118 | $5,028 |
| Pfizer | 50 | $4,957 |
| Bayer | 19 | $2,613 |
| Boston Scientific | 24 | $1,506 |
| AstraZeneca | 11 | $306 |
| Blue Earth Diagnostics | 13 | $257 |
| Myriad Genetic Laboratories, Inc. | 5 | $224 |
| Merck | 10 | $211 |
| Novartis | 7 | $168 |
| Myovant Sciences Inc. | 6 | $136 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Siemens Medical Solutions USA, Inc. | 2 | $107 |
| Sumitomo Pharma America, Inc. | 3 | $79 |
| Seagen Inc. | 1 | $76 |
| Caris MPI, Inc. | 3 | $69 |
| Radius Health, Inc. | 3 | $56 |
| Foundation Medicine, Inc. | 3 | $43 |
| Progenics Pharmaceuticals, Inc. | 2 | $42 |
| Palette Life Sciences, Inc. | 1 | $37 |
| Clovis Oncology, Inc. | 2 | $32 |
| Teleflex LLC | 1 | $23 |
| Telix Pharmaceuticals | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $19 |
How this compares
$258,260 in reported general payments places this provider in the 90th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Corpus Christi
- Daniel GomezHouston$8.7M
- Neil DesaiDallas$8.6M
- Chad TangHouston$7.7M
- James WelshHouston$5.1M
- Caroline ChungHouston$3.7M
- Karen HoffmanHouston$2.6M
- Clifton FullerHouston$1.6M
- Robert TimmermanDallas$1.5M
- Steven LinHouston$1.5M
- Chenyang WangHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.